MyFinsight
Home
Blog
About
Contact
Proceeds from exercise of
stock options
$1,470,659
Net cash provided by
financing activities
$1,470,659
Net increase
(decrease) in cash and cash...
-$182,425,828
Canceled cashflow
$1,470,659
Proceeds from sales and
maturities of marketable...
$30,998,448
Stock-based compensation
$5,918,055
Prepaid expenses and
other assets
-$979,776
Changes in lease
liabilities
$641,285
Depreciation and
amortization
$534,670
Receivables
-$59,167
Net cash provided by
(used in) investing...
-$154,641,596
Net cash used in
operating activities
-$29,254,891
Canceled cashflow
$30,998,448
Canceled cashflow
$8,132,953
Purchase of marketable
securities
$174,893,062
Net loss
-$33,941,345
Purchases of property and
equipment
$5,121,709
Payments for
construction in progress
$4,703,521
Payments for leasehold
improvements
$921,752
Accounts payable and
accrued expenses
-$3,081,283
Amortization/accretion of note
premiums/discounts
-$358,625
Other
$6,591
Back
Back
Cash Flow
CAPRICOR THERAPEUTICS, INC. (CAPR)
CAPRICOR THERAPEUTICS, INC. (CAPR)
source: myfinsight.com